We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...
We initiate coverage of Heijmans, a contractor focused on the Dutch market, with an Outperform rating and a TP of € 36.5 (DCF based). The Dutch residential market is finally recovering, and we believe Heijmans is well-positioned to benefit due to its land bank and property development arm, driving up revenues while EBITDA margins are expected to exceed 8.5% in the Living unit. Heijmans is also benefitting from strong demand from the infrastructure and energy markets, allowing for soli...
>Key takeaways: cautious guidance, less ambitious on Moncler and work to be done on enhancing the portfolio - 1/ Cautious guidance for 2025 (but the consensus too high), due to embedded effects. A good line-up for 2025: several launch initiatives are planned: Montblanc Explorer (new line), Jimmy Choo Man, Coach (2 new editions: Woman and Man), Solferino (new proprietary brand - niche perfumes / 10 lines listed in Paris for the story telling), Lacoste (extension of L12...
>Principaux éléments : guidance prudente, moins ambitieux sur Moncler et un travail à réaliser pour enrichir le portefeuille - 1/ Guidance 2025 prudente (mais CSS trop haut), compte tenu des effets embarqués. Bon line-up en 2025: plusieurs initiatives de lancements sont prévues : Montblanc Explorer (nouvelle ligne), Jimmy Choo Man, Coach (2 nouvelles déclinaisons : Woman et Man), Solferino (nouvelle marque propriétaire - parfums de niche / 10 lignes en référence à Par...
Interparfums management released cautious sales prospects for 2025 yesterday with limited growth despite the roll-out of Lacoste Original. Although we are slightly more aggressive than management, we have notched down our FY25 sales estimate from EUR960m to EUR950m. Buy reiterated with EUR54 vs EUR
>The management guides to 2025 growth of “just” 4%e - Ahead of its CMD today, Interparfums announced:1/ The fine tuning of its 2024 guidance: i/ 2024 sales are maintained in a range of between € 880-890m), ii/ the 2024 underlying operating margin is now projected to exceed 19%e, or >€ 170m est. (vs close to 19%, i.e. € 167-170m est. previously),2/ 2025 sales between € 910m and € 930m est. (i.e. +4% at the midpoint) , vs css >€ 950m est.;3/ A 2025 operat...
>Le management guide sur une croissance 2025 de « seulement » 4%e - En amont de son CMD, qui se tiendra aujourd’hui, Interparfums communique sur :1/ Le fine tuning de sa guidance 2024 : i/ le CA 24e est maintenu à une fourchette comprise entre 880-890 M€ précédemment), ii/ la MOp. courante 2024 devrait désormais dépasser les 19%e, soit >170 M€e (vs proche de 19% ie. 167-170 M€e jusqu’ici).2/ Un CA 2025 compris entre 910 et 930 M€e (ie. +4% en milieu de fourc...
>Conference call feedback: Q3 2024 results, management of residual value - During a conference call, Sixt’s management issued an update on the group’s Q3 results as well as the growth outlook. Our key takeaways:Revenues in Q3 were up 10%, benefiting from brisk demand during the summer season (Germany: +7%; Europe: +5%; US: +21%). In parallel, the group successfully grew its fleet, +9% (but at a lower level than its revenue growth) leading to an improvement in the...
>Feedback conference call : résultats T3 24, gestion de la valeur résiduelle - Lors d’une conférence téléphonique, le management de Sixt est revenu sur les réalisations du groupe au T3 ainsi que les perspectives de croissance. Nous retenons essentiellement :Le CA au T3 ressort en progression de 10%, bénéficiant d’une demande soutenue durant la saison estivale (Allemagne : +7% ; Europe : +5% ; US : +21%). En parallèle, le groupe a réussi à augmenter sa flotte, +9%...
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the submission of the updated regulatory file for LUMEVOQ® gene therapy to the French medicines safety agency Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) to prepare for the restart of the early access (AAC) program in France. The submission documents the successful ...
PARIS--(BUSINESS WIRE)-- Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible au PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives rétiniennes et les troubles du système nerveux central, annonce aujourd'hui la soumission du dossier réglementaire actualisé pour la thérapie génique LUMEVOQ® à l'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) pour préparer la reprise du programme d'accès compassionnel (AAC) en France. Le d...
ASM informs the market about ASMPT ceasing possible privatization talks Almere, The Netherlands November 12, 2024, 6:00 p.m. CET ASM international N.V. (Euronext Amsterdam: ASM) informs the market that ASMPT, in which ASM has a shareholding of approximately 25%, announced that it ceased discussions in relation to a possible privatization of ASMPT. ASMPT Ltd. (“ASMPT), in which ASM is a shareholder, announced on October 14, 2024, that its board had received a preliminary non-binding approach from an independent third party (the “Potential Offeror”) in relation to a possible privatiz...
>Q3 EBT at € 246.4m (ODDO BHF: € 262.6m; Css: € 251m); margin at 19.8% - Sixt SE has just released its Q3/9M 2024 results, which were overall in line with expectations marked by: 1/ Q3 Consolidated revenue of € 1,242.3m (2% above estimates), up +10% y-o-y (after an increase of 10.3% in H1) (ODDO BHF: € 1221.6m; consensus: € 1217m), driven by still dynamic demand in all segments and solid market prices which is reassuring, especially in North America (32% of consolidat...
>Q3 EBT at € 246.4m (ODDO BHF: € 262.6m; Css: € 251m); margin at 19.8% - Sixt SE has just released its Q3/9M 2024 results, which were overall in line with expectations marked by: 1/ Q3 Consolidated revenue of € 1,242.3m (2% above estimates), up +10% y-o-y (after an increase of 10.3% in H1) (ODDO BHF: € 1221.6m; consensus: € 1217m), driven by still dynamic demand in all segments and solid market prices which is reassuring, especially in North America (32% of consolidat...
EQS-News: Sixt SE / Key word(s): Quarter Results Record summer at SIXT: Q3 revenue at an all-time high of EUR 1.24 billion, EBT of EUR 246 million at previous year’s level, margin of around 20% 12.11.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Record summer at SIXT: Q3 revenue at an all-time high of EUR 1.24 billion, EBT of EUR 246 million at previous year’s level, margin of around 20% Revenue at an all-time high: EUR 1.24 billion, an increase of 10% compared to Q3 2023 and around 60% compared to the last pre-Covid year...
EQS-News: Sixt SE / Schlagwort(e): Quartalsergebnis Rekord-Sommer bei SIXT: Umsatz in Q3 mit 1,24 Mrd. Euro auf Allzeit-Hoch, EBT mit 246 Mio. Euro auf Vorjahresniveau, Rendite bei rund 20% 12.11.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Rekord-Sommer bei SIXT: Umsatz in Q3 mit 1,24 Mrd. Euro auf Allzeit-Hoch, EBT mit 246 Mio. Euro auf Vorjahresniveau, Rendite bei rund 20% Umsatz auf Allzeit-Hoch: 1,24 Mrd. Euro, ein Anstieg von 10% zu Q3 2023 und von rund 60% zum letzten Vor-Corona-Jahr 2019 Starke operative P...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.